Introduction {#S0001}
============

The misuse of antibiotics is the primary factor selecting for antibiotic resistance, followed by the unnecessary supplementation of animal feed with antibiotics.[@CIT0001] Among the various types of antibiotics, colistin, a last resort chemotherapeutic option against carbapenem-resistant bacteria, is faced with a growing clinical challenge of antibiotic resistance.[@CIT0002] Until recently, colistin resistance was believed to be chromosomally mediated; however, the discovery of plasmid-mediated colistin resistance via *mcr-1* in 2015 revealed colistin resistance was capable of horizontal transmission.[@CIT0003],[@CIT0004] Subsequent studies reported that *mcr-1* is expressed in many bacteria worldwide.[@CIT0003],[@CIT0005]--[@CIT0007] Moreover, new *mcr* genotypes were reported, and eight more *mcr* genes (*mcr-2* to *mcr-9* )[@CIT0008] have been reported since the discovery of *mcr-1*.[@CIT0009]--[@CIT0015] Currently, PCR-based methods are the most widely adopted to detect *mcr* genes,[@CIT0016] however, owing to the presence of several genotypes of *mcr* genes and their ability to undergo horizontal gene transfer; PCR assays are limited in clinical practice, including the primary-care hospitals and the basic quarantine stations. Therefore, a rapid, efficient, reliable, and economical method to detect *mcr* genes is urgently required.

Loop-mediated isothermal amplification (LAMP) is a nucleic acid amplification method conducted at a constant temperature, based on auto-cycling strand displacement of DNA synthesis by Bst DNA polymerase.[@CIT0017] It is a promising method to detect nucleic acids, with advantages including the non-requirement of thermo-cycling instruments, higher sensitivity, and less time-consumption. With the rapid development of the LAMP method, studies have reported increasing applications of LAMP, including nucleic acid detection from bacteria,[@CIT0018],[@CIT0019] viruses,[@CIT0020] and parasites.[@CIT0021]--[@CIT0023] Zou et al first reported the application of LAMP to detect *mcr-1*, achieving higher sensitivity than traditional PCR.[@CIT0024] Imirzalioglu et al used the eazyplex SuperBug *mcr-1* kit, developed to rapidly detect *mcr-1*.[@CIT0025] However, owing to the multiple *mcr* genotypes, a single LAMP cannot detect all potential target genes, thereby yielding incomplete information for nucleic acid detection.

In this study, we aimed to develop a restriction endonuclease-based multi-LAMP method to detect multiple *mcr* genes. We established a triple-LAMP system for the most extensively propagated *mcr* genes (*mcr-1, mcr-3*, and *mcr-4*) in People's Republic of China. A double-LAMP system for *mcr-2* and *mcr-5* has also been established to detect all *mcr* genes (*mcr-6* to *mcr-9* had not been discovered when this study started). We designed and screened 5 sets of primers for each *mcr-1* to *mcr-5* genes and assessed the sensitivity and specificity of the assay through electrophoresis and visual detection, using clinical samples from hospitals in Guangzhou, People's Republic of China. Primers for this assay were modified with restriction endonucleases and were used combinatorially for the multi-LAMP assay, and specific *mcr* genes were detected from the band numbers and fragment lengths of the digested LAMP-amplified products.

Materials and methods {#S0002}
=====================

Primers design {#S0002-S2001}
--------------

Sequences of *mcr-1* to *mcr-5* genes were downloaded from GenBank database: *mcr-1* (accession number: KX886345.1); *mcr-2* (accession number: NG_051171.1); *mcr-3* (accession number: MG026622.1); *mcr-4* (accession number: MG026621.1); and *mcr-5* (accession number: MG241339.1). To determine the optimum primers, 3 primer sets for each gene were designed by using Primer Explorer (version 5, <http://primerexplorer.jp/lampv5e/index.html>) ([Table S1](#ST0003)). Each primer set comprises 6 primers: a forward inner primer (FIP), backward inner primer (BIP), outer forward primer (F3), outer backward primer (B3), and two loop primers (LF and LB) to accelerate the LAMP reaction.[@CIT0017] All primers were synthesized by Tianyi Biotech Co. (Dongguan, People's Republic of China).

Samples preparation {#S0002-S2002}
-------------------

In our study, five positive controls harboring *mcr-1* to *mcr-5* genes were used, wherein *mcr-1, mcr-3*, and *mcr-4* were screened in our laboratory, *mcr-2* was obtained from South China Agricultural University, and *mcr-5* was obtained from China Agricultural University ([Table 1](#T0001){ref-type="table"}). Three multidrug-resistant bacterial strains (two *Escherichia coli* and one *Klebsiella pneumonia*) devoid of *mcr* genes, identified via PCR in our previous studies,[@CIT0026] were used as negative controls. All strains were stored in 30% (w/v) glycerol broth at −80°C. The strains were cultured in Luria-Bertani culture medium (OXOID, Hampshire, UK) supplemented with 2% colistin at 37°C overnight. Bacterial genomic DNA was extracted using the boiling method and recovered in 200 μL RNase-free ddH~2~O. pMD19-T vector containing *mcr-1* to *mcr-5* DNA fragments was constructed separately, as previously described.[@CIT0027],[@CIT0028] The recombinant plasmids were diluted 10-fold serially to yield 10^8^ copies/μL to 10^2^ copies/μL.Table 1*mcr* genes and other resistant genes used in this studyNO.Genetic typesSourceGene Role1*mcr-1E. coli*Positive control2*mcr-2*PlasmidPositive control3*mcr-3E. coli*Positive control4*mcr-4E. coli*Positive control5*mcr-5*PlasmidPositive control6*bla*~KPC-2~*K. pneumonia*Negative control7*bla*~NDM-1~*E. coli*Negative control8*bla*~CTX-M-9~*E. coli*Negative control

LAMP reaction {#S0002-S2003}
-------------

The LAMP reaction was carried out in a 25 μL reaction mixture that contained 12.5 µL LAMP-Reaction Mix \[20 mM Tris-HCl (pH 8.8), 10 mM (NH~4~)~2~SO~4~, 8 mM MgSO~4~, 10 mM KCl, 0.8 M betaine, 0.1% Tween-20, 1.4 mM deoxy-ribonucleotide triphosphates (dNTP)\], 1 µL Bst 2.0 polymerase (New England Biolabs, 8,000 units/mL), 1.25 µL primer mix (2 μM each of FIP and BIP, 0.25 µM each of F3 and B3, and 1 µM each of LF and LB) ([Table 2](#T0002){ref-type="table"}), 8.25 µL nuclease-free water, and 2 µL DNA lysate. The mixture was incubated for 60 mins at 64°C in a heated, thermostatically controlled water bath.Table 2The primer sequences of multi-LAMP and PCR for *mcr-1* to *mcr-5* genesTarget genesmulti-LAMPReferencePCRReferencePrimersSequences(5ʹ-3ʹ)aPrimersSequences(5ʹ-3ʹ)***mcr-1***F3TGATGCAGCATACTTCTGTGThis studyFAGTCCGTTTGTTCTTGTGGC[@CIT0016]B3GACCGTGCCATAAGTGTCFIPGCGATGGGATAGGTTTGGCT*AAGCTT*GTGTTGCCGTTTTCTTGACBIPTGCTGACGATCGCTGTCG*AAGCTT*GCACATAGCGATACGATGATRAGATCCTTGGTCTCGGCTTG[@CIT0016]LFAAGGTAAGATTGGCGGTCGLBCTACTGATCACCACGCTGTT***mcr-2***F3CAAAGACGCCGTGCAGACThis studyFCAAGTGTGTTGGTCGCAGTT[@CIT0016]B3CAGAATACGCCGTCGATGTFIPACTGCACATGGTCAGCACGC*AAGCTT*GAGCGTAAGCCACGCCTABIPGGCTATGGCCGTGAGACTTTCC*AAGCTT*GCCACACGATGTCACTTGGRTCTAGCCCGACAAGCATACC[@CIT0016]LFACCGACGACGAACACCACLBCTTGCCAAAGTTGATGGCTTG***mcr-3***F3CATTACCAATATTGCTTGTTGCThis studyFAAATAAAAATTGTTCCGCTTATG[@CIT0016]B3TTGGCTGGAACAATCTCACFIPGCTAACGCCTCATTTTGATTGG*AAGCTT*GCACTTCTTATCGCACTTAGBIPTCAAAGGGATTCTAACTCGTGC*AAGCTT*GCAATAACCGCAATCACTATRAATGGAGATCCCCGTTTTT[@CIT0016]LFTCATTGTGTAACTAACGATTGCLBCCTATCGATGTTTGCATCACTT***mcr-4***F3TGAGTTAAGGCGTTACATTGTThis studyFTCACTTTCATCACTGCGTTG[@CIT0016]B3CGCATGAGCTAGTATCGTTAAFIPTTACGACTGGCATTCTTCGCA*AAGCTT*CTATTTGCAGACGCCCATBIPAGTGGTTGTTGTGGGTGAAACT*AAGCTT*AGCATTGGTTGGCTTGTTARTTGGTCCATGACTACCAATG[@CIT0016]LFTCTAGGCCAAGTTGTTGGTATTLBCGCGCTCAATGAGCTATCA***mcr-5***F3CAATGGAGAATGCTGCCCTAThis studyFATGCGGTTGTCTGCATTTATC[@CIT0016]B3GCGTGGGTATCAGCACATCFIPAGCCCGTTCGTAAAACCCTGAC*AAGCTT*CTTGTTGGTTGCAGCCGTBIPAGCGGTAATGATGCGCAGCG*AAGCTT*CATGACTGGCCACAGACCRTCATTGTGGTTGTCCTTTTCTG[@CIT0016]LFCTCGCAATCCACCACACGGATLBTGGCGCTCTCGCCATGA[^2]

PCR assay {#S0002-S2004}
---------

A PCR assay was performed to compare its sensitivity and the clinical detection rates with those of the LAMP assay. Each plasmid sample was amplified in 20 µL reaction mixtures containing 10 µL PCR Master Mix (Tiangen Biotech Co., Ltd., Beijing, People's Republic of China), 400 pM primers ([Table 2](#T0002){ref-type="table"}), and 1 µL DNA template. The cycling conditions were as follows: 3 mins at 95°C; 30 cycles of 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C; 5 mins at 72°C. The PCR products were analyzed electrophoretically on a 2% agarose gel, followed by ethidium bromide staining. Images were obtained using the (Bio-Rad, Hercules, CA, USA).

Detection of LAMP products {#S0002-S2005}
--------------------------

LAMP products were detected using two methods: visual detection[@CIT0029] and electrophoresis. For visual detection, SYBR Green I was added into the LAMP products, where the positive reactions yielded green coloration; while the negative ones gave yellow. For electrophoresis, the LAMP products were stained with GoldView TM, analyzed electrophoretically on a 2% agarose gel, and photographed.

Multi-LAMP detection {#S0002-S2006}
--------------------

The triple-LAMP assay was performed using a set of three primer pairs each, for *mcr-1, mcr-3*, and *mcr-4*. The double-LAMP assay was performed using a set of three primer pairs each, for *mcr-2* and *mcr-5*. The amplification was carried out in a 25 μL reaction mixture as the LAMP reaction. Both of the amplification products of the triple-LAMP and double-LAMP were diluted by twofold, digested using Thermo Scientific Fast Digest Hind at 37°C for 15 mins and then analyzed electrophoretically on a 2% agarose gel. Through the electrophoresis results, different types of *mcr* genes were distinguished based on the band numbers and band locations on electropherograms.

Results {#S0003}
=======

Primer selection and modification {#S0003-S2001}
---------------------------------

Fifteen primer sets were designed to detect *mcr-1* to *mcr-5* (3 sets for each gene) as shown in [Table S1](#ST0003). To determine the optimum primers, LAMP reactions using different primer sets were conducted under the same conditions, and electropherograms of the LAMP products were compared. According to the electrophoretic analysis, the optimum primer sets were selected. The locations and sequences of selected optimal primer sets are shown in [Figure 1](#F0001){ref-type="fig"}. Additionally, for the multi-LAMP, we modified the selected optimal FIPs and BIPs by inserting the Hind restriction sites between F1c and F2 and between B1c and B2, respectively ([Table 2](#T0002){ref-type="table"}).Figure 1Locations and sequences of *mcr* genes used to design multi-LAMP primers. (**A--E**) The nucleotide sequences of the target strands of *mcr-1* to *mcr-5* genes. Right arrows indicate the original sequences and left arrows indicate the complementary sequences.

Sensitivity of the LAMP assay {#S0003-S2002}
-----------------------------

To determine the sensitivity of the LAMP assay, purified genomic DNA templates were detected via 10-fold serial dilution of known copies numbers of DNA template molecules. Comparative PCR assays were also conducted using the same DNA templates. LAMP products were further analyzed visually ([Figure 2A](#F0002){ref-type="fig"}--[E](#F0002){ref-type="fig"}) and via agarose gel electrophoresis ([Figure 2F](#F0002){ref-type="fig"}--[O](#F0002){ref-type="fig"}). These results indicated that the detection limit of the LAMP assay was 10^4^ copies/µL for *mcr-1, mcr-2, mcr-4* and *mcr-5*, and 10^5^ copies/µL for *mcr-3*. Comparatively, agarose gel electrophoresis was conducted for the PCR products, wherein the detection limits were 10^5^ copies/µL for *mcr-1* to *mcr-5* genes. All reactions were carried out at least in triplicate.Figure 2Sensitivity of the loop-mediated isothermal amplification (LAMP) and polymerase chain reaction (PCR) assays. (**A--E**) Visual detection of the LAMP amplification products of *mcr-1* to *mcr-5* genes with SYBR Green I. (**F--J**) Agarose gel electrophoresis was conducted for the LAMP products of *mcr-1* to *mcr-5* genes. (**K--O**) Comparative agarose gel electrophoresis analysis of products of the PCR assay and the corresponding LAMP assay. Lane M, Trans 2K plus II DNA marker; Lanes 1--7, serial 10-fold dilutions of templates from 10^8^ copies/µL to 10^2^ copies/µL; Lane 8, negative (water).

Specificity of the LAMP assay {#S0003-S2003}
-----------------------------

Assay specificity was assessed via direct visual detection through the addition of SYBR Green I during the reaction, followed by confirmatory evaluation via agarose gel electrophoresis. Three non-*mcr* genes (*bla*~KPC-2~, *bla*~NDM-1~, and *bla*~CTX-M-9~) were analyzed in addition to *mcr-1* to *mcr-5* genes. Our results revealed that *mcr-1* was positively identified via LAMP only when amplification was performed using the *mcr-1* primer set, while all non-*mcr-1* genes tested negative ([Figure 3A](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). The *mcr-2* to *mcr-5* genes were similarly analyzed, indicating that this LAMP method was specific for *mcr-1* to *mcr-5* genes ([Figure 3B](#F0003){ref-type="fig"}--[E](#F0003){ref-type="fig"} and [G](#F0003){ref-type="fig"}--[J](#F0003){ref-type="fig"}). All reactions were carried out at least in triplicate.Figure 3Specificity of the loop-mediated isothermal amplification (LAMP) assays. (**A--E**) Visual detection of the LAMP amplification products with SYBR Green I. (**F--J**) Agarose gel electrophoresis of the LAMP products. Lane M: Trans 2K plus II DNA marker; Lanes 1--5: *mcr-1* to *mcr-5* genes; Lane 6: *bla*~KPC-2~; Lane 7: *bla*~NDM-1~; Lane 8: *bla*~CTX-M-9~; Lane 9: negative (water).

Multi-LAMP detection of *mcr* genes {#S0003-S2004}
-----------------------------------

To generate the multi-LAMP system, endonuclease analysis was applied. For cleavage sites in *mcr-1* to *mcr-5* genes, enzyme digestion was performed using Hind restriction enzyme. For the triple-LAMP, the target sequence of *mcr-1* was cleaved into 2 segments, *mcr-3* into 2 segments and *mcr-4* into 3 segments ([Figure 4A](#F0004){ref-type="fig"}). For the double-LAMP, the target sequence of *mcr-2* was cleaved into 3 segments and *mcr-5* into 2 segments ([Figure 4B](#F0004){ref-type="fig"}). The sizes of the digested products were consistent with those predicted for *mcr-1* to *mcr-5* genes. The DNA sequencing of the digested products confirmed the specificity of the amplification (data not shown). Through restriction endonuclease analysis of the amplification products, *mcr-1* to *mcr-5* genes were successfully distinguished ([Figure 4A](#F0004){ref-type="fig"}, *mcr-1, mcr-3*, and *mcr-4*; [Figure 4B](#F0004){ref-type="fig"}, *mcr-2* and *mcr-5*).Figure 4Multiplex loop-mediated isothermal amplification (multi-LAMP) detection. Agarose gel electrophoresis and enzyme digestion analysis of *mcr* genes was performed for the multi-LAMP products on 2% agarose gel. (**A**) Lane M, Trans 2K plus II DNA marker; Lane 1, restriction enzyme digestion of *mcr-1* multi-LAMP products, 170 bp, 115 bp respectively; Lane 2, restriction enzyme digestion of *mcr-3* multi-LAMP products, 260 bp, 155 bp respectively; Lane 3, restriction enzyme digestion of *mcr-4* multi-LAMP product, 270, 230, and 185 bp respectively; Lane 4, restriction enzyme digestion of mixed *mcr-1, mcr-3*, and *mcr-4* multi-LAMP products, 260, 225, 170, 120, and 90 bp; Lane 5, negative (water). (**B**) Lane M, Trans 2K plus II DNA marker; Lane 1, restriction enzyme digestion of *mcr-2* multi-LAMP products, 220, 175, and 140 bp respectively; Lane 2, restriction enzyme digestion of *mcr-5* multi-LAMP products, 120 bp, 90 bp respectively; Lane 3, restriction enzyme digestion of mixed *mcr-2* and *mcr-5* multi-LAMP products, 215, 170, 140, 120, and 90 bp, respectively; Lane 4: negative (water).

Multi-LAMP detection of clinical samples {#S0003-S2005}
----------------------------------------

To further evaluate the accuracy of multi-LAMP, 58 clinical bacterial samples from a previous study[@CIT0026] were subjected to the present assay. Among the 58 clinical samples, 12 were positive for *mcr-1*, five for *mcr-3*, and one for *mcr-4*, while the remaining 40 samples were *mcr* negative. The clinical bacterial samples were also subjected to traditional PCR analysis, which also revealed twelve *mcr-1*-positive samples, five *mcr-3-*positive samples, one *mcr-4*-positive sample, and forty negative samples, consistent with the results of multi-LAMP. Therefore, these findings reveal that multi-LAMP described here showed good consistency with conventional PCR analyses.

Discussion {#S0004}
==========

Colistin is a polypeptide antibiotic, belonging to the family of polymyxins. Colistin was first reported to treat infections by Gram-negative bacteria in the late 1940s. Owing to its risk of nephrotoxicity and neurotoxicity, colistin was not popularized in clinical treatment. Later, antibiotics acting on emerging carbapenem-resistant superbugs were deemed critical because of their high morbidity and mortality, framing colistin as a significant therapeutic alternative.[@CIT0002] Emerging colistin resistance, therefore, has confounding implications in patient care. Before 2015, the mechanisms underlying colistin were known only to involve chromosomal mutations; hence, its spread was expected to be limited to vertical transmission, which was usually stable, incapable of spreading to other bacteria and imposing a fitness cost upon the bacteria. The discovery of *mcr* genes signifies plasmid-meditated colistin resistance, implying a new horizontal transmission channel for the propagation of the *mcr* genes, increasing their rapid transmission risk and range. Moreover, colistin abuse via its supplementation in animal feed contributed to its dissemination through horizontal gene transfer.[@CIT0004] Therefore, analysis of *mcr* genes is necessary to identify colistin resistance and control its horizontal transmission.

This study established a novel multi-LAMP system to detect multiple *mcr* genes, with the establishment of a triple-LAMP for *mcr-1, mcr-3*, and *mcr-4*, as well as a double-LAMP for *mcr-2* and *mcr-5*. We designed 15 primer pairs for the conserved sequences of *mcr-1* to *mcr-5* genes (3 for each gene). Because *mcr* genes share significant homology, we screened the best primer sets by considering *mcr* genes as positive controls. Five primer sets each for *mcr-1* to *mcr-5* genes were screened out and determined to be the optimal primers for the LAMP assay. Subsequent specificity analyses confirmed the optimal nature of these primer sets. We compared the sensitivity of LAMP with that of traditional PCR analysis, reporting that the detection limit of the LAMP assay was 10-fold that of conventional PCR analysis. This high sensitivity and specificity rendered LAMP suitable for early screening in clinical settings, especially in the primary medical institutions. Through restriction digestion of the LAMP products based on band numbers and fragment lengths, we successfully distinguished *mcr-1, mcr-3*, and *mcr-4*, as well as *mcr-2* and *mcr-5*, thereby enabling multiplex detections of *mcr* genes. Additionally, we applied this multi-LAMP method to clinical samples to assess the reliability of our methods, with results being consistent with those of conventional PCR analyses.

Compared with traditional PCR, the present method exhibited the following advantages: 1) high specificity and sensitivity and ease of operation; 2) multiplex detections of *mcr* genes using the same detection system, thus reducing manual operation; 3) a total operating time of \<60 mins, as opposed to 90 mins to detect *mcr* genes via conventional PCR analysis; 4) greater user-friendliness than conventional PCR analysis, with no requirement of specialized instruments and complicated operations. These advantages render the multi-LAMP assay promising for clinical application, especially in resource limited medical institutions.

This study has some limitations; the sensitivity and specificity of the multi-LAMP assay are relatively poorer when applied to samples containing more than one *mcr* genes. Nonetheless, according to other previous studies and data from our on-going experiments, it is rare for a single strain to contain multiple *mcr* genes in clinical samples (0.01% is according to our data; unpublished data). Therefore, our approach is applicable in most practical situations. Moreover, gene sets (*mcr-1, mcr-3*, and *mcr-4*) and gene sets (*mcr-2* and *mcr-5)* were successfully detected, where *mcr-1, mcr-3*, and *mcr-4* are the most prevalent *mcr* genes in People's Republic of Chinaand *mcr-2* and *mcr-5*, not yet detected in humans, complemented the whole *mcr* gene family. With newer *mcr* genes being reported (*mcr-6* to *mcr-9* genes during our study in 2018) in future studies, continuous efforts are needed to track newly reported *mcr* genes and to establish a multi-LAMP system encompassing all *mcr* genes.

In our future studies, we intend to investigate the LAMP-based methods for drug resistance genes of these *mcr* genes and to continuously track the newly reported *mcr* genes. Upon analyzing more *mcr* genes and using larger sample sizes, we intend to further assess the potential of multi-LAMP and further validate its diagnostic power. These results provide critical insights into the efficacy of this method for future clinical applications related to antibiotic resistance. Our results potentially contribute to the prevention of antibiotic resistance in health care settings by providing a system of early detection of antibiotic resistance and prescribing patterns at national, regional, and local levels.

Conclusion {#S0005}
==========

In conclusion, we established a restriction digestion-based multi-LAMP method, which successfully detected *mcr-1, mcr-3*, and *mcr-4* via a triple-LAMP and *mcr-2* and *mcr-5* via a double-LAMP. We anticipate that this method could rapidly help screen *mcr* genes and other drug-resistant genes in a variety of clinical settings. To our knowledge, this is the first study reporting the application of LAMP in the detection of *mcr-2* to *mcr-5* genes and the first time that multi-LAMP has been applied to detect *mcr* genes.
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Table S1The primer sequences of LAMP for *mcr-1* to *mcr-5* genesTarget genePrimersSequences (5ʹ-3ʹ)Reference*mcr-1* (1)F3TGATGCAGCATACTTCTGTGThis studyB3GACCGTGCCATAAGTGTCFIPGCGATGGGATAGGTTTGGCTGTGTTGCCGTTTTCTTGACBIPTGCTGACGATCGCTGTCGGCACATAGCGATACGATGATLFAAGGTAAGATTGGCGGTCGLBCTACTGATCACCACGCTGTT*mcr-1* (2)F3TGCTACCAAGTTTGCTTGTThis studyB3CGTCTTTGGCGTGATAAATGFIPAGACTTGCCACGATCAAGCCTTAAGGTGGATTATCCGACTTGBIPGCGTTCAGCAGTCATTATGCCGTAGATTGGCATGATCGGATLFCAATCGGCGCATCAAACCLBCGCTGCGTAGCTATGTCA*mcr-1* (3)F3ATACCGCCAAATACCAAGAAAThis studyB3CATCTAAGCCAACGAGCATFIPGCAGCTTATCCATCACGCCTTGATACGCTGGATCGCTTGBIPGCCGATTATAAATCCGCGACCAGCGGCATTCGTTATAAGGALFGTCCGAATTATTATCACGCCACLBCAACGCCATCTGCAACAC*mcr-2* (1)F3ACGCCTAGTGGTGTTCGTThis studyB3GCGGTCAAGCGTATCTAGCFIPAACTTTGGCAAGCTGCGGGAATGCTGACCATGTGCAGTTCBIPTCGACGGCGTATTCTGTGCCGGTATTTGGCGGTATCGACALFAGTCTCACGGCCATAGCCLBGTGTATGTTCAGCTATTTGGGTCA*mcr-2* (2)F3GGGTAAGCTTGCCAGTATCGThis studyB3AGCTGCGGGAAAGTCTCAFIPCTCGGCTTGGTGGTCTGCACCACTGCGCCAACAGACACBIPGAGCGTAAGCCACGCCTAGTGCGGCCATAGCCATTGAACTGLFGGCGTCTTTGGCATGATAGATGLBGTGTTCGTCGTCGGTGAGA*mcr-2* (3)F3CAAAGACGCCGTGCAGACThis studyB3CAGAATACGCCGTCGATGTFIPACTGCACATGGTCAGCACGCGAGCGTAAGCCACGCCTABIPGGCTATGGCCGTGAGACTTTCCGCCACACGATGTCACTTGGLFACCGACGACGAACACCACLBCTTGCCAAAGTTGATGGCTTG*mcr-3* (1)F3CATTACCAATATTGCTTGTTGCThis studyB3TTGGCTGGAACAATCTCACFIPGCTAACGCCTCATTTTGATTGGTTGCACTTCTTATCGCACTTABIPTCAAAGGGATTCTAACTCGTGCGCAATAACCGCAATCACTATLFTCATTGTGTAACTAACGATTGCLBCCTATCGATGTTTGCATCACTT*mcr-3* (2)F3CATTACCAATATTGCTTGTTGCThis studyB3TTGGCTGGAACAATCTCACFIPGCTAACGCCTCATTTTGATTGGTGCACTTCTTATCGCACTTAGBIPTCAAAGGGATTCTAACTCGTGCGCAATAACCGCAATCACTATLFTCATTGTGTAACTAACGATTGCLBCCTATCGATGTTTGCATCACTT*mcr-3* (3)F3CATTACCAATATTGCTTGTTGCThis studyB3TTGGCTGGAACAATCTCACFIPGCTAACGCCTCATTTTGATTGGGCACTTCTTATCGCACTTAGTBIPTCAAAGGGATTCTAACTCGTGCGCAATAACCGCAATCACTATLFTCATTGTGTAACTAACGATTGCLBCCTATCGATGTTTGCATCACTT*mcr-4* (1)F3TGAGTTAAGGCGTTACATTGTThis studyB3CGCATGAGCTAGTATCGTTAAFIPTTACGACTGGCATTCTTCGCACTATTTGCAGACGCCCATBIPAGTGGTTGTTGTGGGTGAAACTAGCATTGGTTGGCTTGTTALFTCTAGGCCAAGTTGTTGGTATTLBCGCGCTCAATGAGCTATCA*mcr-4* (2)F3TGTTCGAAACAACAGTGAGTThis studyB3CGCATGAGCTAGTATCGTTAAFIPTTACGACTGGCATTCTTCGCATTGAGCACTATTTGCAGACGBIPAGTGGTTGTTGTGGGTGAAACTAGCATTGGTTGGCTTGTTALFGCCAAGTTGTTGGTATTCCATGLBCGCGCTCAATGAGCTATCA*mcr-4* (3)F3CATGGAATACCAACAACTTGGThis studyB3CGGCGAGGATCATAGTCTFIPAGTTTCACCCACAACAACCACTAGATGCGAAGAATGCCAGBIPCAAGCCAACCAATGCTCATACCTGCCGCATGAGCTAGTATLFTAGGTTTAGTGTTCGGGTTACGLBGGGCTGATTGCGTTTAACG*mcr-5* (1)F3CAATGGAGAATGCTGCCCTAThis studyB3GCGTGGGTATCAGCACATCFIPAGCCCGTTCGTAAAACCCTGACCTTGTTGGTTGCAGCCGTBIPAGCGGTAATGATGCGCAGCGCATGACTGGCCACAGACCLFCTCGCAATCCACCACACGGATLBTGGCGCTCTCGCCATGA*mcr-5* (2)F3ATGGATGTGCTGATACCCACThis studyB3AGTACGAGAGCACGAGGACFIPCGAATGCCCGAGATGACGTAGTCTTCGTGAAAACAAGCCGCBIPGACTGAACAGGCGTCATCGTCACCTTGTTCTTGAGGCCCTCLFGCAGGAGTGATCAAATAGCGAALBGCAGACGAAGCAAGGGAAG*mcr-5* (3)F3GCTGCCCTACTTGTTGGTTGThis studyB3CGAAGCGGCTTGTTTTCACFIPTACCGCTTGTTTCCAGCCCGCAGCCGTATCCGTGTGGTBIPCTGGCGCTCTCGCCATGATTGAAGCGTGGGTATCAGCACLFACCCTGACTCTCGCAATCCLBTCCATGGGTCTGTGGCC

[^1]: These authors contributed equally to this work

[^2]: **Note:** ^a^Underlining indicates the restriction enzyme sites of Hind.

    **Abbreviations:** F3, Forward Outer Primer; B3, Backward Outer Primer; FIP, Forward Internal Primer; BIP, Backward Internal Primer; LF, Loop Forward Primer; LB, Loop Backward Primer; F, Forward Primer; R, Reverse Primer.
